Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Stopped In 2013 the FDA put a temporary hold on the trial and the Phase II portion of this study was cancelled.

Conditions

• Acute Myeloid Leukemia
• High Risk Myelodysplastic Syndrome

Interventions

• DRUG: Azacitidine
• DRUG: Cytarabine
• DRUG: Tosedostat

Sponsor

M.D. Anderson Cancer Center

Collaborators

• [object Object]